Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

30 sept. 2024 19h07 HE | Source: Clinuvel Pharmaceuticals Limited

CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP

CLINUVEL has filed a Canadian New Drug Submission for SCENESSE® (afamelanotide) for erythropoietic protoporphyria (EPP).
23 avr. 2020 02h08 HE | Source: Clinuvel Pharmaceuticals Limited

SCENESSE® to be Prescribed in China

MELBOURNE, Australia and HANGZHOU, China, April 23, 2020 (GLOBE NEWSWIRE) -- Australian-based company CLINUVEL is launching SCENESSE® (afamelanotide 16mg) in the People’s Republic of China for the...
25 juin 2018 06h00 HE | Source: Clinuvel Pharmaceuticals Limited

FDA to Review Australian Drug for Genetic Disorder of Absolute Light Intolerance

MELBOURNE, Australia, June 25, 2018 (GLOBE NEWSWIRE) -- In a landmark case, the US Food and Drug Administration (FDA) has begun a review of an innovative drug developed for patients who carry a rare...